Heart Disease Trial, Recruiting NCT04741711 Sponsor: Central Hospital, Nancy, France Condition: Heart Disease
Back to Heart Disease

Heart Disease Trial, Recruiting

NCT04741711
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years of age or older (male or female)
  • You have been diagnosed with heart failure (any type)
  • Your heart failure diagnosis was made more than 3 months ago
  • You do not currently have significant signs of fluid build-up in your body, such as crackling sounds in the lungs or significant leg swelling beyond mild ankle swelling
  • You are affiliated with the French social security system
  • You have received full information about the study and are willing to sign a consent form

Who may not be able to join:

  • You have had a natriuretic peptide blood test (a specific heart-related test) done in the last 30 days that is already available at the time of your enrolment visit
  • You have a lung or chest lining condition (such as severe emphysema, long-term fluid around the lungs, or lung scarring) that would make lung ultrasound scans unreliable
  • You have been diagnosed with, or are suspected of having, a condition called cardiac amyloidosis (a disease where abnormal proteins build up in the heart)
  • You have a serious problem with one of your heart valves that is not caused by another condition
  • You are pregnant, in labour, or currently breastfeeding
  • You are under a legal protection order such as guardianship or a similar arrangement (confirm with trial site)
  • You are currently restricted of your freedom by a court or administrative decision
  • You are currently receiving involuntary psychiatric care under specific French public health laws (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 5 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +33 3 83 15 74 96

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
15 May 2023
Est. completion
15 June 2026

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Death within 30 days (composite endpoint); Hospitalization for heart failure within 30 days (composite endpoint); Changes in N-terminal pro b-type natriuretic peptide (NtProBNP) between randomization and D30 (composite endpoint)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov